Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events
Table 2
Details of the line of anti-PD-1 therapy, duration of treatment, survival, and subsequent treatment on progression.
PN
Anti-PD-1 Therapy
Line of anti-PD-1 therapy
ECOG PS
Response
DOT (months)
PFS (months)
TPTD (months)
Overall Survival (months)
Subsequent therapy
1
Pembrolizumab
second
1
PR
4.1
24.6
20.5
39.3
Radiation, pembrolizumab with development of pembrolizumab induced psoriasis
2
Pembrolizumab
second
0
CR
4.6
20.2
15.6
49.0
Radiation, pembrolizumab with TLR9 agonist without immune toxicities
3
Nivolumab
second
1
CR
2.6
49.4+
46.8+
49.4
NA
4
Pembrolizumab
first
1
SD
2.3
3.0
0.7
4.6
Dabrafenib with trametinib
5
Pembrolizumab
second
0
PR
3.5
30.3+
26.9+
30.3
NA
6
Pembrolizumab
second
1
CR
11.5
36.3+
24.8+
36.3
NA
7
Pembrolizumab
first
1
PR
4.8
18.1
13.3
23.4
Radiation
8
Pembrolizumab
second
1
SD
4.8
7.3
2.6
28.3
Craniotomy and surgical resection, stereotactic radiosurgery, vemurafenib with cobimetinib
9
Pembrolizumab
first
0
CR
6.5
17.5+
11.0+
17.5
NA
10
Pembrolizumab
first
1
CR
6.9
21.9+
15.0+
21.9
NA
11
Pembrolizumab
first
0
CR
9.7
30.1+
20.5+
30.1
NA
12
Pembrolizumab
first
0
CR
0.7
23.0+
22.3+
23.0
NA
13
Pembrolizumab
second
2
PR
4.6
16.8
12.2
25.0
Radiation, dabrafenib with trametinib
14
Pembrolizumab
first
0
PR
5.0
19.3
14.3
31.8
Pembrolizumab with TLR9 agonist without immune toxicity, radiation, vemurafenib with cobimetinib
15
Pembrolizumab
third
1
CR
11.5
37.3+
25.8+
37.3
NA
16
Pembrolizumab
first
0
PD
1.3
1.6
0.2
5.4
Temozolomide
PN: patient number. ECOG PS: Eastern Cooperative Oncology Group Performance Status. PR: partial response. CR: complete response. Alive. SD: stable disease. PD: progressive disease. Censored, no evidence of progression. DOT: Duration of treatment. TPTD: time to progression from treatment discontinuation.
